Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Cabozantinib is a tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.
- Mechanism
- Curator reviewed · 1 reference
Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.
- Primary indication
- Cabozantinib, marketed under the brand name Cometriq, is indicated for the treatment of progressive, metastatic medullary thyroid cancer (MTC).Curator reviewed · 16 structured indications
- Formula / weight
- C28H24FN3O5 · 501.514 g/mol (avg)
- First approval
- Canada, 2018 · United States, 2012 · European Union, 2016
- Code names
- BMS-907351 · XL-184
- Brand names
- Cabometyx
- Cometriq
Resolves to
Clinical / RWD
Structure
InChIKey
ONIQOQHATWINJY-UHFFFAOYSA-NSMILESCOC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2What you can answer from here — as of September 13, 2026
13Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
Which drugs share a target with Cabozantinib, and which of those have an active Phase 3 trial?